|
시장보고서
상품코드
2055246
폐렴구균 백신 시장 : 백신 유형별, 대상 집단별, 투여 경로별, 유통 채널별, 지역별Pneumococcal Vaccines Market, By Vaccine Type, By Target Population, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
폐렴구균 백신 시장은 2026년 98억 8,000만 달러로 추정되고, 2033년에 141억 8,000만 달러에 이를 것으로 예상되고 있습니다. 또한, 2026-2033년 CAGR 5.3%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 98억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 5.30% | 2033년 시장 규모 예측 : | 141억 8,000만 달러 |
세계 폐렴구균 백신 시장의 성장은 전 세계 폐렴구균 감염증 발생률 증가와 각국 정부의 예방접종 프로그램 확대와 같은 요인에 힘입어 이루어지고 있습니다. 또한, 폐렴구균 백신 접종에 대한 대중의 인식이 높아지는 것도 시장 성장을 뒷받침할 가능성이 있습니다. 그러나 폐렴구균 백신의 개발 및 제조에 따른 높은 비용은 시장 성장을 저해하는 요인이 될 수 있습니다. 합리적인 가격에 효과적인 백신을 개발하기 위한 지속적인 연구 개발 활동은 가까운 미래에 새로운 기회를 가져올 가능성이 있습니다.
시장 역학
세계 폐렴구균 백신 시장의 성장은 주로 전 세계적으로 폐렴구균(Streptococcus pneumoniae)에 의한 폐렴, 수막염 및 기타 중증 감염증의 유병률이 증가하고 있는 데 힘입고 있습니다. 세계보건기구(WHO)에 따르면, 폐렴은 5세 이하 유아의 주요 사망 원인 5위 안에 들고 있습니다. 또한, 국가 예방접종 계획을 통해 예방접종 프로그램을 추진하기 위한 정부 자금의 증액 및 관련 노력은 시장 성장을 가속할 가능성이 있습니다. 그러나 폐렴구균 백신의 연구 개발 및 제조 비용이 높다는 점은 시장 확대를 저해할 가능성이 있습니다. 새로운 다가 폐렴구균 제제의 안전성과 유효성을 평가하기 위한 진행 중인 임상시험이 시장 성장을 가속할 가능성이 있습니다. 신흥국에서는 의료 인프라가 점차 정비되고 있어, 시장 관계자들에게 큰 기회가 되고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 폐렴구균 백신 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업의 주요 성과, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 ‘세계 폐렴구균 백신 시장 보고서’는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 폐렴구균 백신 시장 : 백신 유형별, 2021-2033년
제5장 세계의 폐렴구균 백신 시장 : 대상 집단별, 2021-2033년
제6장 세계의 폐렴구균 백신 시장 : 투여 경로별, 2021-2033년
제7장 세계의 폐렴구균 백신 시장 : 유통 채널별, 2021-2033년
제8장 세계의 폐렴구균 백신 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고 문헌과 조사 방법
LSH 26.06.23Pneumococcal Vaccines Market is estimated to be valued at USD 9.88 Bn in 2026 and is expected to reach USD 14.18 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9.88 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.30% | 2033 Value Projection: | USD 14.18 Bn |
Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.
Market Dynamics
Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
- By Vaccine Type (Revenue, USD Bn, 2021 - 2033)
- Pneumococcal Conjugate Vaccines (PCVs)
- PCV13 (Prevnar 13/Prevenar 13)
- PCV10 (Synflorix)
- PCV7 (Prevnar/Prevenar)
- Pneumococcal Polysaccharide Vaccines (PPVs)
- PPSV23 (Pneumovax 23)
- PPSV14 (Pneumo 14)
- By (Revenue, USD Bn, 2021 - 2033) Target Population
- Adults (a‰¥ 65 years)
- Children (< 5 years)
- High-Risk Adults (18-64 years)
- By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Intramuscular
- Subcutaneous
- By (Revenue, USD Bn, 2021 - 2033) Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- Sanofi
- CSL Limited
- Serum Institute of India Pvt. Ltd.
- Vaxcyte, Inc.
- Astellas Pharma Inc.
- Panacea Biotec Ltd.
- Walvax Biotechnology Co., Ltd.
- Beijing Minhai Biotechnology Co., Ltd.
- Merck KGaA
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Novartis AG
- Johnson & Johnson
- Biovac
- Bharat Biotech
- Inovio Pharmaceuticals, Inc.
- Hilleman Laboratories Pvt. Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Pneumococcal Vaccines Market, By Vaccine Type
- Global Pneumococcal Vaccines Market, By Target Population
- Global Pneumococcal Vaccines Market, By Route of Administration
- Global Pneumococcal Vaccines Market, By Distribution Channel
- Global Pneumococcal Vaccines Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pneumococcal Conjugate Vaccines (PCVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- PCV13 (Prevnar 13/Prevenar 13)
- PCV10 (Synflorix)
- PCV7 (Prevnar/Prevenar)
- Pneumococcal Polysaccharide Vaccines (PPVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- PPSV23 (Pneumovax 23)
- PPSV14 (Pneumo 14)
5. Global Pneumococcal Vaccines Market, By Target Population, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adults (≥ 65 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Children (< 5 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- High-Risk Adults (18-64 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Pneumococcal Vaccines Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Pneumococcal Vaccines Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026,2028 & 2033, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Target Population, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Sub-region, 2021 - 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc (GSK)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CSL Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vaxcyte, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Panacea Biotec Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Walvax Biotechnology Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Beijing Minhai Biotechnology Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biovac
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Inovio Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hilleman Laboratories Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
